Esperion Therapeutis.Inc. buy WatchMen
Summary
This prediction ended on 15.10.24 with a price of €1.94. The BUY prediction by WatchMen for Esperion Therapeutis.Inc. saw massive gains of 137.85%. WatchMen has 40% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | -6.461% | -6.461% | 49.136% |
| iShares Core DAX® | -0,98 % | -4,72 % | 4,79 % |
| iShares Nasdaq 100 | 1,16 % | 1,88 % | 20,23 % |
| iShares Nikkei 225® | -1,59 % | -5,39 % | 31,35 % |
| iShares S&P 500 | -0,28 % | 0,33 % | 13,91 % |
Comments by WatchMen for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by WatchMen for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
04.10.25
04.10.26
08.10.25


